Plain-English translation of NCT06787482 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called ACE Retino, a peptide-based treatment designed to help protect and potentially regenerate the retina in people with three types of eye diseases: inherited retinal dystrophies, age-related macular degeneration, and diabetic retinopathy. The medication is taken as a sublingual dose (under the tongue), which allows it to be absorbed into your bloodstream without needles or invasive procedures. Researchers want to see if this treatment is safe and whether it can improve eyesight or slow vision loss.
Retinal diseases like these are leading causes of blindness worldwide, and current treatment options are limited. This medication works by reducing inflammation and oxidative stress in the eye, and by supporting the regrowth of damaged retinal cells—offering hope for people facing progressive vision loss.
You likely qualify if…
You likely don't qualify if…
You will take one milliliter of the medication four times daily under your tongue for six months. During the 12-month study, you'll have regular eye exams and blood tests to monitor your vision, retinal health, and how your body is responding to the treatment. The study involves visits to the clinic where researchers will test your eyesight, take images of your retina, and check for any side effects.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Egypt